# Compass Therapeutics, Inc.: overview CMPX · Nasdaq · CIK 1738021 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cmpx.md) · [Financials](/companies/cmpx/financials.md) · [Filings](/companies/cmpx/filings.md) · [Insiders](/companies/cmpx/insiders.md) Latest reported revenue: [$0](/filings/0001171843-26-001337.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001171843-26-001337). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | not reported | [0.0](/filings/0001171843-25-005261.md) | [0.0](/filings/0001171843-25-007005.md) | [0.0 d](/filings/0001171843-26-001337.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(11.1) d](/filings/0001171843-25-007005.md) | [(9.2) d](/filings/0001171843-26-001337.md) | [(13.2)](/filings/0001171843-26-003006.md) | [(11.8) d](/filings/0001171843-26-005295.md) | [(10.9) d](/filings/0001171843-25-007005.md) | [(13.3) d](/filings/0001171843-26-001337.md) | [(17.4)](/filings/0001171843-26-003006.md) | [(14.9) d](/filings/0001171843-26-005295.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001171843-25-001106.md) | [0.9](/filings/0001171843-26-001337.md) | [0.0](/filings/0001171843-26-001337.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(6661.8%)](/filings/0001171843-26-001337.md) | not reported | | Net margin | % | not reported | not reported | not reported | [(5808.8%)](/filings/0001171843-26-001337.md) | not reported | | Diluted EPS | $ per share | [(1.31)](/filings/0000950170-22-004156.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(21.2)](/filings/0001171843-23-001691.md) | [(34.3)](/filings/0001171843-24-001516.md) | [(40.6)](/filings/0001171843-25-001106.md) | [(44.9)](/filings/0001171843-26-001337.md) | [(49.2)](/filings/0001171843-26-001337.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cmpx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $39.4m | 17,990,782 | | Added +1,199,973 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $33.3m | 15,219,994 | | Unchanged | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $30.9m | 14,101,159 | | Reduced −206,220 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $24.7m | 11,281,781 | | Added +1,775,701 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $21.8m | 9,953,653 | | Added +3,258,677 | | [ENAVATE SCIENCES GP, LLC](/funds/1953107.md) | 2026-06-30 | $17.1m | 7,788,150 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $17.0m | 7,757,060 | | Reduced −1,788,406 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.4m | 6,118,782 | | Added +81,607 | | [Palo Alto Investors LP](/funds/1306923.md) | 2026-06-30 | $12.8m | 5,831,813 | | Added +4,317,309 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $10.3m | 4,713,247 | | Added +3,867,027 | ## Recent filings [All 355 filings](/companies/cmpx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-22 | 12:30 ET | [8-K](/filings/0001171843-26-006162.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-006162 | | 2026-08-06 | 12:00 ET | [10-Q](/filings/0001171843-26-005295.md) | Quarterly report, period 2026-06-30 | 0001171843-26-005295 | | 2026-08-06 | 11:30 ET | [8-K](/filings/0001171843-26-005292.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005292 | | 2026-07-01 | 21:00 ET | [8-K](/filings/0001171843-26-004428.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-004428 | | 2026-06-23 | 21:45 ET | [8-K](/filings/0001171843-26-004224.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001171843-26-004224 | | 2026-06-11 | 20:00 ET | [8-K](/filings/0001171843-26-004068.md) | 5.07 Shareholder vote results | 0001171843-26-004068 | | 2026-05-05 | 12:01 ET | [10-Q](/filings/0001171843-26-003006.md) | Quarterly report, period 2026-03-31 | 0001171843-26-003006 | | 2026-05-05 | 11:30 ET | [8-K](/filings/0001171843-26-003005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003005 | | 2026-04-29 | 12:08 ET | [DEF 14A](/filings/0001140361-26-017649.md) | Proxy statement, period 2026-06-10 | 0001140361-26-017649 | | 2026-04-27 | 11:30 ET | [8-K](/filings/0001171843-26-002720.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-002720 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001171843-26-001337.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1738021 - Tickers: CMPX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.